FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977965664> ?p ?o ?g. }

• W2977965664 endingPage "5206" @default.
• W2977965664 startingPage "5206" @default.
• W2977965664 abstract "Abstract Acute lymphoblastic leukemia (ALL) relapsing after allogeneic stem cell transplantation (allo-SCT) is usually associated with poor outcome. T-ALL patients relapsing early post-allo-SCT or relapsed B-ALL patients who have failed currently available targeted and immunotherapies need an effective salvage therapy. We herein describe 3 cases where minimal residual disease (MRD) negative remission was achieved in very high-risk relapsing ALL patients with the use of daratumumab with or without nelarabine. Patient 1: A 24-year-old male diagnosed in May 2016 with T lymphoblastic lymphoma. Following ECOG 2993-based induction, his PET became negative. Additional 3 high-dose methotrexate and 3 consolidation cycles were prescribed followed by maintenance therapy. In August 2017, he relapsed in the bone marrow (BM) and central nervous system, and a second remission (CR2) was achieved after therapy with mitoxantrone + cytarabine. He underwent allo-SCT from his matched brother in CR2. Three and a half months after the transplant he experienced a third relapse. Two cycles of nelarabine were administrated followed by daratumumab 16mg/kg in a myeloma like protocol. BM at the end of 2 nelarabine cycles demonstrated remission but with 0.09% residual disease cells on flow cytometry. After the first 2 months of daratumumab, BM confirmed MRD eradication. One dose of 5x105/kg donor lymphocyte infusion (DLI) was also prescribed. Patient 2: A 43-year-old female diagnosed with T-ALL in February 2017. Her disease was refractory to ECOG 2993-based induction and remission was achieved only after a second-line therapy with mitoxantrone + cytarabine. She was referred to allo-SCT from her matched sister, engrafted well and developed grade 2-3 acute graft-versus-host disease which responded well to steroids. Five months post-transplant an extra-medullary relapse was diagnosed in her eye and skin, while MRD was identified in her BM. The same regimen of 2 cycles of nelarabine followed by daratumumab 16mg/kg was prescribed. Extra-medullary disease was eliminated and so was the residual BM disease. One dose of 5x105/kg DLI was also prescribed. The case of patient 3 has just been published (Ganzel C, et al. Haematologica, June 2018). In brief, this is a 21-year-old man diagnosed 7 years ago with Ph+ B-ALL. Daratumumab was prescribed to treat his 7th relapse after he had been treated with multiple TKIs, including ponatinib, underwent two allo-SCTs and received immunotherapy with 2 different anti CD19 and anti CD22 CAR-T cell agents. In parallel to daratumumab, vincristine was administered every 4 weeks as well as daily ponatinib. Molecular remission following daratumumab was confirmed by PCR for BCR/ABL. Kinetics of response and duration of follow-up: For the patient with Ph+ ALL, daratumumab was prescribed while overt disease was present in the BM but peripheral counts were low (WBC=2,000, ANC=1,000, PLT=95,000). Hematologic remission was confirmed after 1 month and molecular remission after 4 months. Unfortunately, 6 months after the first infusion of daratumumab he relapsed again and now (one year post-daratumumab administration) he is alive and treated with bortezomib and gemtuzumab ozogamicin. Both T-ALL patients achieved morphologic remission with nelarabine and received one DLI. MRD was identified in BM examination following nelarabine cycles and its elimination was confirmed in the BM at the end of the first 2 months of daratumumab (a total of 8 weekly infusions). Currently, these patients are 20 and 22 weeks following relapse and are alive and in molecular remission. In all 3 patients we noticed no significant side effects that could be related to daratumumab infusion. Peripheral WBC and PLT count dynamics are shown in figure 1. Treatment of ALL patients who relapse with high-risk features is a great challenge. Herein we report three consecutive patients who achieved MRD negativity with daratumumab. Daratumumab can be combined with other effective agents in a simple and safe protocol that may be delivered even to heavily pre-treated patients. Although larger studies with longer follow-up are required, this novel approach may offer new hope for patients with a devastating disease such as relapsed ALL. Disclosures Ofran: Novartis: Other: Served on a Novartis advisory board." @default.
• W2977965664 created "2019-10-10" @default.
• W2977965664 creator A5026942316 @default.
• W2977965664 creator A5031117400 @default.
• W2977965664 creator A5033941202 @default.
• W2977965664 creator A5042528560 @default.
• W2977965664 creator A5068847117 @default.
• W2977965664 creator A5072468961 @default.
• W2977965664 creator A5073083193 @default.
• W2977965664 creator A5073265954 @default.
• W2977965664 creator A5085103789 @default.
• W2977965664 date "2018-11-29" @default.
• W2977965664 modified "2023-10-16" @default.
• W2977965664 title "Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse" @default.
• W2977965664 doi "https://doi.org/10.1182/blood-2018-99-111258" @default.
• W2977965664 hasPublicationYear "2018" @default.
• W2977965664 type Work @default.
• W2977965664 sameAs 2977965664 @default.
• W2977965664 citedByCount "6" @default.
• W2977965664 countsByYear W29779656642019 @default.
• W2977965664 countsByYear W29779656642020 @default.
• W2977965664 countsByYear W29779656642021 @default.
• W2977965664 countsByYear W29779656642022 @default.
• W2977965664 crossrefType "journal-article" @default.
• W2977965664 hasAuthorship W2977965664A5026942316 @default.
• W2977965664 hasAuthorship W2977965664A5031117400 @default.
• W2977965664 hasAuthorship W2977965664A5033941202 @default.
• W2977965664 hasAuthorship W2977965664A5042528560 @default.
• W2977965664 hasAuthorship W2977965664A5068847117 @default.
• W2977965664 hasAuthorship W2977965664A5072468961 @default.
• W2977965664 hasAuthorship W2977965664A5073083193 @default.
• W2977965664 hasAuthorship W2977965664A5073265954 @default.
• W2977965664 hasAuthorship W2977965664A5085103789 @default.
• W2977965664 hasBestOaLocation W29779656641 @default.
• W2977965664 hasConcept C126322002 @default.
• W2977965664 hasConcept C141071460 @default.
• W2977965664 hasConcept C143998085 @default.
• W2977965664 hasConcept C2776364478 @default.
• W2977965664 hasConcept C2776694085 @default.
• W2977965664 hasConcept C2776755627 @default.
• W2977965664 hasConcept C2777478702 @default.
• W2977965664 hasConcept C2778020697 @default.
• W2977965664 hasConcept C2778041864 @default.
• W2977965664 hasConcept C2778283404 @default.
• W2977965664 hasConcept C2778461978 @default.
• W2977965664 hasConcept C2779429289 @default.
• W2977965664 hasConcept C2779823535 @default.
• W2977965664 hasConcept C2780775027 @default.
• W2977965664 hasConcept C2780923524 @default.
• W2977965664 hasConcept C2781119759 @default.
• W2977965664 hasConcept C2909962599 @default.
• W2977965664 hasConcept C2911091166 @default.
• W2977965664 hasConcept C71924100 @default.
• W2977965664 hasConceptScore W2977965664C126322002 @default.
• W2977965664 hasConceptScore W2977965664C141071460 @default.
• W2977965664 hasConceptScore W2977965664C143998085 @default.
• W2977965664 hasConceptScore W2977965664C2776364478 @default.
• W2977965664 hasConceptScore W2977965664C2776694085 @default.
• W2977965664 hasConceptScore W2977965664C2776755627 @default.
• W2977965664 hasConceptScore W2977965664C2777478702 @default.
• W2977965664 hasConceptScore W2977965664C2778020697 @default.
• W2977965664 hasConceptScore W2977965664C2778041864 @default.
• W2977965664 hasConceptScore W2977965664C2778283404 @default.
• W2977965664 hasConceptScore W2977965664C2778461978 @default.
• W2977965664 hasConceptScore W2977965664C2779429289 @default.
• W2977965664 hasConceptScore W2977965664C2779823535 @default.
• W2977965664 hasConceptScore W2977965664C2780775027 @default.
• W2977965664 hasConceptScore W2977965664C2780923524 @default.
• W2977965664 hasConceptScore W2977965664C2781119759 @default.
• W2977965664 hasConceptScore W2977965664C2909962599 @default.
• W2977965664 hasConceptScore W2977965664C2911091166 @default.
• W2977965664 hasConceptScore W2977965664C71924100 @default.
• W2977965664 hasIssue "Supplement 1" @default.
• W2977965664 hasLocation W29779656641 @default.
• W2977965664 hasOpenAccess W2977965664 @default.
• W2977965664 hasPrimaryLocation W29779656641 @default.
• W2977965664 hasRelatedWork W1966099453 @default.
• W2977965664 hasRelatedWork W2327443350 @default.
• W2977965664 hasRelatedWork W2329316959 @default.
• W2977965664 hasRelatedWork W2349679547 @default.
• W2977965664 hasRelatedWork W2485045656 @default.
• W2977965664 hasRelatedWork W2521864917 @default.
• W2977965664 hasRelatedWork W2890971980 @default.
• W2977965664 hasRelatedWork W2977965664 @default.
• W2977965664 hasRelatedWork W2988830689 @default.
• W2977965664 hasRelatedWork W3092704081 @default.
• W2977965664 hasVolume "132" @default.
• W2977965664 isParatext "false" @default.
• W2977965664 isRetracted "false" @default.
• W2977965664 magId "2977965664" @default.
• W2977965664 workType "article" @default.